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Introduction: Myocardial dysfunction is common after out-of-hospital cardiac arrest (OHCA) and high-sensitivity
troponin T (hs-TnT) levels may provide incremental prognostic information to established risk indices.
Methods: A total of 155 patients with OHCA and a shockable rhythm (98% ventricular fibrillation; OHCA-VF/VT)
had blood samples drawn within six hours of admission. Blood samples were also available after 24 hours, 48 hours,
and 96 hours in subsets of patients. The endpoints of the study were hospital mortality and neurological status and
mortality after one year.
Results: Admission hs-TnT levels were higher than the 99-percentile of the general population (14 ng/L) in all
patients (range 18 to 17837 ng/L). Admission hs-TnT levels were associated with acute coronary artery occlusion,
time to return of spontaneous circulation, heart failure, and renal function. Admission hs-TnT levels were higher in
one-year non-survivors compared to survivors (median 747 (quartile 1 to 3, 206 to 1061) ng/L versus 345 (184 to 740)
ng/L, P =0.023) and in patients with a poor versus a favorable neurological outcome (739 (191 to 1061) ng/L versus 334
(195 to 716) ng/L, P =0.028). However, hs-TnT measurements did not add prognostic information to established risk
variables in multivariate analyses. hs-TnT levels measured during the hospitalization for OHCA-VF/VT correlated
closely with admission levels (r ≥0.63) and were inferior to Simplified Acute Physiology Score II (SAPS II) scores for
the prediction of events during follow-up. hs-TnT dynamics did not discriminate between survivors and non-survivors
or between a poor versus a favorable neurological outcome.
Conclusion: hs-TnT levels are elevated in critically ill patients with OHCA-VF/VT, but do not improve risk prediction.Introduction
The long-term morbidity and mortality of successfully
resuscitated patients following ventricular arrhythmia-
induced out-of-hospital cardiac arrest (OHCA) are still
high [1,2]. Standard treatment in patients with OHCA is
targeted to support organ function and has included
temperature control to alleviate cerebral injury [3],
which is known to cause most deaths after OHCA [4-6].* Correspondence: helge.rosjo@medisin.uio.no
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unless otherwise stated.However, as post-cardiac arrest shock affects two thirds
of all OHCA patients [5] and contributes to mortality
during follow up [4-6], cardiac biomarkers may provide
additional prognostic information to established risk
factors in OHCA [7]. Early myocardial stunning in
post-cardiac arrest shock will also lead to systemic
hypotension, which will limit the potential for brain
recovery after OHCA [8].
Cardiac-specific troponin I and T are part of the
contractile apparatus of cardiomyocytes, but leak into the
circulation after cardiomyocyte injury [9]. Thus, symptoms
suggestive of myocardial ischemia and dynamic troponin
elevations (rise and/or fall) are required for the diagnosis oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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universal definition of myocardial infarction [10]. Chest
pain patients with elevated troponin levels have a worse
prognosis than patients with normal troponin levels, but
this excessive risk can be reduced by early angiography
and percutaneous coronary intervention [11]. Hence,
in patients with chest pain troponins are useful for
diagnostic and prognostic assessment, as well as for
selecting patients who may benefit from invasive therapy.
In contrast, whether troponins provide clinically relevant
information in patients with ventricular fibrillation or
tachycardia (VF/VT) and OHCA has not been established
[7]. Previous studies, using sensitive or high-sensitivity
(hs) troponin assays suggest that troponins have insufficient
accuracy for diagnosing acute coronary artery occlusion in
the setting of cardiac arrest [12-14]. However, troponins
could still be of interest in OHCA by identifying the patient
at highest risk of developing post-cardiac arrest syndrome
[8]. To be clinically relevant, studies should be performed
in OHCA patients receiving contemporary therapy, includ-
ing therapeutic hypothermia (TH) [3,8]. Furthermore, as hs
troponin assays have been found to be superior to previous
generation troponin assays for prognostic assessment across
the spectrum of cardiovascular disease [15-18], hs troponin
assays should be tested for prognostic utility also in patients
with OHCA. In cardiac arrest patients, prognosis differ
markedly depending on the initially observed rhythm
(shockable versus non-shockable) [19]. Thus, studies
assessing the prognostic utility of troponins should pre-
ferably encompass a homogeneous patient population; that
is, OHCA-VF/VT patients. Accordingly, in this study of
OHCA patients with a shockable rhythm we wanted to (1)
identify factors that influence hs-TnT levels and (2) assess
whether hs-troponin T (hs-TnT) measurements improve
prediction of morbidity and mortality, short- and long-term.
Methods
Study design
This is a substudy of FINNRESUSCI, an observational
prospective multicenter study performed by the FinnishFigure 1 Flow chart of the study. OHCA, out-of-hospital cardiac arrest; VIntensive Care Consortium that comprised 21 of the
22 ICUs in Finland [20]. The study was conducted
according to the Declaration of Helsinki and approved
by the Ethics Committee of Helsinki University Hospital
with written informed consent for blood sampling obtained
from a legal representative. Inclusion criteria for the
FINNRESUSCI Study were (1) OHCA, (2) successful
resuscitation, (3) age >18 y, and (4) post-resuscitation
care in a participating ICU.
The main study focused on post-resuscitation care for
OHCA, and these results have previously been reported
[20], including that 86% of unconscious patients with a
shockable rhythm were treated with TH (33-34°C). In short,
from 1 March 2010 to 28 February 2011 a total of 548
adult patients with OHCA admitted to an ICU were
identified. A total of 311 patients had a shockable
rhythm (OHCA-VF/VT), and blood samples (after an
informed consent) were available within 6 h of ICU
admission in 155 (50%) of these patients (Figure 1). No
restrictions were implemented regarding techniques of
induction or maintenance of TH in the FINNRESUSCI
Study. However, the majority of Finnish ICUs use
endovascular cooling devices. Patients with a non-shockable
rhythm were excluded from this substudy because these
patients have a clearly worse prognosis and are subjected to
less standardized treatment than patients with a shockable
rhythm [19,21].
We collected information on age, gender, weight and
height, and previous medical history in an electronic
case report form. Body mass index (BMI) was calculated
by weight (kg)/(height (m))2. We collected information
on the cardiac arrest episode, including the time to return
of spontaneous circulation (ROSC) according to the Utstein
style [22]. We also collected information on treatment
during the ICU stay and whether the hospitalization was
complicated by pneumonia or sepsis. Coronary angiography
was performed at the discretion of the attending physicians
at the different centers. We considered coronary artery
intervention during the ICU stay as indicative of an acute
coronary artery occlusion. The simplified acute physiologyF, ventricular fibrillation.
Table 1 Patient characteristics in the biomarker substudy
and the patients with out-of-hospital cardiac arrest (OHCA)
and a shockable rhythm in the main FINNRESUSCI Study
Biomarker substudy Main study
(n =155) (n =311)
Age 63 (56 to 72) 63 (56 to 72)
Male sex, n (%) 132 (85%) 253 (81%)
Coronary artery disease, n (%) 50 (32%) 113 (36%)
Diabetes mellitus, n (%) 33 (21%) 59 (19%)
Hypertension, n (%) 70 (45%) 140 (45%)
Heart failure, n (%) 23 (15%) 45 (15%)
SAPS II score 58 (40 to 69) 54 (39 to 66)
Resuscitation
Witnessed cardiac arrest, n (%) 143 (92%) 288 (93%)
Bystander CPR, n (%) 105 (68%) 195 (63%)
Time to ROSC, minutes 20 (14 to 29) 20 (14 to 27)
Treatment during ICU stay
Awake on ICU admission, n (%) 9 (6%) 30 (10%)
Therapeutic hypothermia, n (%) 134 (87%) 241 (78%)
Coronary angiography, n (%) 34 (22%) 72 (23%)
PCI, n (%) 15 (10%) 38 (12%)
Infection
Pneumonia, n (%) 64 (41%) 111 (36%)
Sepsis, n (%) 9 (6%) 14 (5%)
Outcome
Mechanical ventilation, h 50 (40 to 79) 46 (35 to 72)
ICU LOS, days 3.2 (2.2 to 5.0) 2.9 (1.9 to 4.8)
Hospital mortality, n (%) 45 (29%) 96 (31%)
Mortality after 1 year, n (%) 59 (38%) 124 (40%)
CPC 3 to 5 after 1 year, n (%) 65 (42%) 136 (44%)
n, number of patients; hs-TnT, high-sensitivity troponin T; SAPS II, simplified
acute physiology score II; CPR, cardiopulmonary resuscitation; ROSC, return of
spontaneous circulation; PCI, percutaneous coronary intervention; LOS, length
of stay; CPC, cerebral performance categories. Continuous data are presented
as median (quartile 1 to 3).
Røsjø et al. Critical Care 2014, 18:605 Page 3 of 10
http://ccforum.com/content/18/6/605score (SAPS) II was calculated 24 h after ICU admission
excluding points from temperature and negative effects of
sedation on the Glasgow coma scale (GCS). Thus, the best
GCS after resuscitation before start of sedation was
recorded. We included endpoints of the different
phases of the post-cardiac arrest period; that is, hospital
mortality, the mortality after 1 year, and neurological status
at 1 year after cardiac arrest according to recommendations
[8]. Hospital mortality was chosen because SAPS II has
been validated for this endpoint. Neurological status was
assessed by a structured telephone interview with the
patients categorized according to the Pittsburgh cerebral
performance categories (CPC) [22]. Patients with CPC
scores 1 to 2 were categorized as favorable and CPC scores
3 to 5 as having a poor neurological outcome. Hospital
mortality was collected from the medical records and
1-year mortality was obtained from Statistics Finland.
Biochemical analysis
We measured troponin T in serum samples obtained
within 6 h, 24 h, 48 h, and 96 h after cardiac arrest by
the Elecsys TNT hs STAT assay (Roche Diagnostics,
Penzberg, Germany). The hs-TnT assay has an analytical
measurement range of 3 to 10,000 ng/L and the 99th
percentile in the healthy population is 14 ng/L. Samples
with concentrations above the upper limit were diluted
before they were reanalyzed. The analytical characteristics
of the hs-TnT assay have previously been reported for our
laboratory [23]. Creatinine was measured by routine
methods, and we calculated the estimated creatinine
clearance by the Cockcroft-Gault formula [24].
Statistics
We present data as median (quartile (Q) 1 to 3) or absolute
numbers and percentages. Continuous variables demon-
strated a non-normal distribution, as assessed by the
Kolmogorov-Smirnov test, and group differences were ex-
plored by the Mann-Whitney U-test. Categorical variables
were assessed by the Chi-square test or the Fisher exact
test. Variables associated with hs-TnT levels on ICU admis-
sion were assessed by linear regression analysis and the
analysis included age, gender, BMI, estimated creatinine
clearance, comorbidities, information on the cardiac arrest,
and evidence of acute coronary occlusion. The ability of
hs-TnT to predict endpoints during follow up was ex-
plored by univariate and multivariate logistic regression
analyses. The odds ratios (OR) are presented with 95% CI.
Variables significantly associated with the endpoints in
univariate analyses were included in the multivariate
models (forward selection). hs-TnT levels were trans-
formed by the natural logarithm prior to regression ana-
lyses due to a right-skewed distribution. We also assessed
prognostic accuracy of hs-TnT levels by receiver operating
statistics (ROC) with area under the curve (AUC)presented with 95% CI. We used the Wilcoxon matched-
pairs signed-rank test to assess changes in hs-TnT levels
(Δ) from the initial to later time points. A P-value
<0.05 was considered statistically significant. Statistical
analyses were performed with SPSS for Windows version
19.0 (SPSS, Chicago, IL, USA) and MedCalc for Windows,
version 12.1.4.0 (MedCalc Software, Mariakerke, Belgium).
Results
Patient characteristics
Characteristics of the patients in this substudy (n =155)
were comparable to all patients with OHCA and a
shockable rhythm in the main study (n =311) (Table 1). In
total, 152 of 155 patients (98%) had ventricular fibrillation
as the initial rhythm. The median age was 63 (Q1 to Q3
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experienced witnessed cardiac arrest and received bystander
cardiopulmonary resuscitation, and 134 (87%) were treated
with TH (Table 2).
Admission hs-TnT levels
The range of hs-TnT levels within 6 h of admission for
OHCA-VF/VT was 18 to 17,837 ng/L with median level
415 ng/L (Q1 to Q3 199 to 916 ng/L). The prevalence of
diabetes mellitus and heart failure was higher among
patients with hs-TnT levels below the median, while
time to ROSC was longer in patients with supramedian
hs-TnT levels (Table 2). The median hs-TnT level in
patients with acute coronary artery occlusions (n =15) was
1,497 ng/L (Q1 to Q3 753 to 8,875 ng/L) compared to
median 387 ng/L (182 to 815 ng/L) for the other patientsTable 2 Patient characteristics according to hs-TnT levels on i
All patients Quartile (Q
(n =155) (n =78)
hs-TnT, ng/L, range 18-17837 18-41
Age 63 (56 to 72) 63 (56 to
Male sex 132 (85%) 67 (86
Body mass index 26 (24 to 29) 27 (25 to
Creatinine clearance, mL/minute 94 (72 to 126) 100 (77 to
Coronary artery disease, n (%) 50 (32%) 26 (33
Diabetes mellitus, n (%) 33 (21%) 22 (28
Hypertension, n (%) 70 (45%) 35 (45
Heart failure, n (%) 23 (15%) 16 (21
SAPS II score 58 (40 to 69) 54 (37 to
Resuscitation
Witnessed cardiac arrest, n (%) 143 (92%) 73 (94
Bystander CPR, n (%) 105 (68%) 55 (71
Time to ROSC, minutes 20 (14 to 29) 17 (11 to
Treatment during ICU stay
Therapeutic hypothermia 134 (87%) 67 (86
Coronary angiography 34 (22%) 14 (18
PCI 15 (10%) 2 (3%
Infection
Pneumonia 64 (41%) 34 (44
Sepsis 9 (6%) 5 (6%
Outcome
Mechanical ventilation, h 50 (40 to 79) 49 (40 to
ICU LOS, days 3.2 (2.2 to 5.0) 3.1 (2.1 to
Hospital mortality 45 (29%) 18 (23
Mortality after 1 year 59 (38%) 22 (28
CPC 3 to 5 after 1 year 65 (42%) 24 (31
n, number of patients; hs-TnT, high-sensitivity troponin T; SAPS II, simplified acute p
CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation; PCI, p
performance categories. Continuous data are presented as median (quartile 1 to 3).(P <0.001). Admission hs-TnT levels were not associated
with the probability of receiving TH (Table 2).
Admission hs-TnT levels correlated positively with time
to ROSC (r =0.47, P <0.001), SAPS II score (r =0.16,
P =0.045), and duration of mechanical ventilation (r =0.17,
P =0.038), and were inversely correlated to BMI and
estimated creatinine clearance (both r = -0.17, P =0.032).
Evidence of acute coronary artery occlusion (β =0.39,
P <0.001), time to ROSC (β =0.35, P <0.001), history
of heart failure (β = -0.22, P =0.001), and estimated
creatinine clearance (β = -0.17, P =0.013) were associated
with admission hs-TnT levels in multivariate linear regres-
sion analysis (r2 = 0.37). We found close correlations
between admission hs-TnT levels and hs-TnT levels after
24 h (r =0.78); after 48 h (r =0.71); and after 96 h (r =0.63)
(P <0.001 for all).nclusion in the study
) 1 to 2 Quartile (Q) 3 to 4 P-value
(n =77) (Q 1 to 2 versus Q 3 to 4)
5 418-17837 -
70) 64 (57 to 72) 0.25
%) 65 (84%) 0.80
29) 26 (24 to 28) 0.054
129) 88 (67 to 123) 0.13
%) 24 (31%) 0.77
%) 11 (14%) 0.034
%) 35 (46%) 0.94
%) 7 (9%) 0.045
66) 62 (44 to 69) 0.034
%) 70 (91%) 0.53
%) 50 (65%) 0.46
21) 26 (18 to 32) <0.001
%) 67 (87%) 0.84
%) 20 (26%) 0.23
) 13 (17%) 0.003
%) 30 (39%) 0.56
) 4 (5%) 1.00
73) 57 (43 to 89) 0.24
5.2) 3.6 (2.3 to 4.9) 0.51
%) 27 (35%) 0.10
%) 37 (48%) 0.011
%) 41 (53%) 0.005
hysiology score II; SOFA, sequential organ failure assessment score
ercutaneous coronary intervention; LOS, length of stay; CPC, cerebral
Table 3 Prognostic value of high-sensitivity troponin T (hs-TnT) measured ≤24 h after ICU admission as assessed by
receiver operating characteristic curve analysis
Hospital mortality Mortality after 1 year CPC 3 to 5 after 1 year
AUC 95% CI P-value AUC 95% CI P-value AUC 95% CI P-value
Admission (n =155) 0.59 0.51, 0.68 0.10 0.61 0.52, 0.68 0.03 0.60 0.52, 0.68 0.03
24 h (n =150) 0.60 0.51, 0.68 0.05 0.62 0.54, 0.70 0.009 0.62 0.54, 0.70 0.01
Δ hs-TnT (n =150) 0.50 0.42, 0.58 0.99 0.51 0.43, 0.59 0.85 0.51 0.42, 0.59 0.92
CPC, cerebral performance categories; AUC, area under the curve; Δ (delta), change in hs-TnT levels from admission to 24 h.
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neurological outcome (CPC 3 to 5)
Of the 155 patients, 45 patients (29%) died during
the hospitalization. One year after cardiac arrest 59
patients (38%) had died and 65 patients (42%) had a
poor neurological outcome (CPC 3 to 5). Admission
hs-TnT levels were not statistically different between
hospital non-survivors and hospital survivors: 792 ng/L
(191 to 1224 ng/L) versus 387 ng/L (195 to 756 ng/L),
respectively, P =0.08. In contrast, admission hs-TnT
levels were higher in 1-year non-survivors versus survi-
vors (747 ng/L (206 to 1061 ng/L) versus 345 ng/L
(184 to 740 ng/L) P =0.023) and in patients with a
poor neurological outcome compared to a favorable
neurological outcome (739 ng/L (191 to 1061 ng/L) versus
334 ng/L (195 to 716 ng/L), P =0.028). As assessed by
ROC curve analysis, admission hs-TnT levels sepa-
rated between patients that were dead or categorized
as having an unfavorable neurological outcome after
1 year, but did not discriminate regarding hospital
mortality (Table 3). Similar results were also foundTable 4 Comparison of high-sensitivity troponin T (hs-TnT) m
assessed by receiver operating characteristics curve analysis
Hospital mortality Mort
AUC 95% CI P-value AUC
After 24 h(n =150)
SAPS II score 0.76 0.69, 0.83 Reference 0.76
hs-TnT 0.60 0.51, 0.68 0.005 0.62
Δ hs-TnT 0.50 0.42, 0.58 <0.001 0.51
hs-TnT, 48 h (n =138)
SAPS II score 0.76 0.68, 0.83 Reference 0.77
hs-TnT 0.63 0.54, 0.71 0.03 0.65
Δ hs-TnT 0.54 0.45, 0.62 0.006 0.53
hs-TnT, 96 h (n =107)
SAPS II score n.a. 0.75
hs-TnT n.a. 0.62
Δ hs-TnT n.a. 0.51
P-values are for simplified acute physiology score (SAPS) II versus high-sensitivity tr
not calculate results for hospital mortality for measurements after 96 h due to the l
FINNRESUSCI laboratory substudy was 45 patients). AUC, area under the curve; Δ (d
not applicable.for hs-TnT measurements after 24 h, but the accuracy of
hs-TnT levels after 24 h were inferior to SAPS II score for
all endpoints (Table 4).
Most patients demonstrated a reduction in hs-TnT
levels from admission to 24 h (Δ hs-TnT levels), but no
significant differences were found for Δ hs-TnT levels
relating to hospital mortality (median 10 versus 51 ng/L
reduction for non-survivors versus survivors); 1-year
mortality (68 versus 46 ng/L reduction); nor neurological
outcome (median 46 versus 49 ng/L reduction for poor
versus favorable outcome) (Figure 2). In most patients,
hs-TnT levels further decreased 48 h and 96 h after ICU
admission with no differences in hs-TnT dynamics
according to mortality or morbidity during follow up
(Table 4 and Figure 3). By logistic regression analyses,
admission hs-TnT levels (logarithmically transformed)
were neither associated with hospital nor 1-year mortal-
ity, nor with 1-year neurological outcome according to
CPC score (Table 5). In contrast, we found several estab-
lished risk variables in OHCA-VF/VT associated with
mortality and morbidity in our cohort (Table 5).easured ≥24 h after ICU admission and SAPS II score as
ality after 1 year CPC 3 to 5 after 1 year
95% CI P-value AUC 95% CI P-value
0.69, 0.83 Reference 0.78 0.70, 0.84 Reference
0.54, 0.70 0.02 0.62 0.54, 0.70 0.004
0.43, 0.59 <0.001 0.51 0.42, 0.59 <0.001
0.69, 0.83 Reference 0.78 0.70, 0.85 Reference
0.56, 0.73 0.04 0.66 0.57, 0.74 0.03
0.44, 0.61 <0.001 0.51 0.42, 0.59 <0.001
0.68, 0.82 - 0.79 0.70, 0.86 Reference
0.54, 0.70 0.02 0.60 0.50, 0.69 0.005
0.43, 0.59 <0.001 0.53 0.43, 0.63 0.001
oponin T (hs-TnT) levels. CPC, cerebral performance categories; We did
ow number of events in this group (n =17) (total hospital mortality in the
elta), change in hs-TnT levels from admission to later timepoints; n.a.,
Hospital mortality Mortality after 1 year Neurological outcome
Figure 2 hs-TnT levels on admission and after 24 h in patients with OHCA-VF/VT divided according to mortality and neurological
outcome. The horizontal line within the box represents the median concentration, the boundaries of the box quartiles 1-3, and the whiskers
range (maximum value restricted to 1.5 x interquartile range from the median).
Hospital mortality Mortality after 1 year Neurological outcome
Mortality after 1 year Neurological outcome
Figure 3 High-sensitivity troponin T (hs-TnT) levels in the patients with blood samples available also after 48 h (upper panel) and
96 h (lower panel). The horizontal line within the box represents the median concentration, the boundaries of the box quartiles 1 to 3, and the
whiskers range (maximum value restricted to 1.5 × interquartile range from the median).
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Table 5 Associations between variables available <24 h after admission for OHCA-VF/VT and hospital mortality and
1 year outcomes
Hospital mortality Mortality after 1 year CPC 3 to 5 after 1 year
Odds ratio 95% CI P-value Odds ratio 95% CI P-value Odds ratio 95% CI P-value
Univariate analysis
Age 1.05 1.02, 1.09 0.003 1.05 1.02, 1.08 0.002 1.05 1.02, 1.08 0.001
Male 1.19 0.44, 3.24 0.74 1.90 0.70, 5.13 0.21 1.79 0.69, 4.64 0.23
Body mass index 1.006 0.93, 1.09 0.89 1.004 0.94, 1.08 0.91 0.99 0.93, 1.07 0.87
Creatinine clearance 0.99 0.98, 0.99 0.011 0.99 0.98, 1.00 0.052 0.99 0.98, 1.00 0.062
History of coronary artery disease 2.80 1.36, 5.78 0.005 2.68 1.34, 5.36 0.005 2.65 1.33, 5.28 0.006
History of diabetes mellitus 2.56 1.15, 5.69 0.021 1.48 0.68, 3.22 0.33 1.20 0.55, 2.60 0.64
History of hypertension 1.40 0.70, 2.81 0.34 1.16 0.61, 2.23 0.65 1.07 0.56, 2.03 0.83
History of heart failure 3.27 1.32, 8.12 0.010 3.01 1.21, 7.48 0.018 3.08 1.22, 7.77 0.018
Witnessed cardiac arrest 0.38 0.11, 1.23 0.11 0.28 0.08, 0.97 0.044 0.22 0.06, 0.83 0.025
Bystander CPR 0.93 0.45, 1.95 0.86 0.89 0.44, 1.77 0.73 0.78 0.40, 1.54 0.48
Time to ROSC 1.07 1.03, 1.10 <0.001 1.09 1.05, 1.13 <0.001 1.09 1.05, 1.13 <0.001
Therapeutic hypothermia 0.79 0.30, 2.11 0.64 1.27 0.48, 3.35 0.63 1.20 0.47, 3.10 0.70
Coronary angiography 0.26 0.09, 0.79 0.017 0.28 0.11, 0.71 0.008 0.28 0.11, 0.70 0.006
PCI 0.16 0.02, 1.22 0.077 0.10 0.01, 0.79 0.029 0.09 0.01, 0.66 0.019
hs-TnT <6 h 1.25 0.95, 1.64 0.12 1.26 0.97, 1.63 0.09 1.26 0.97, 1.63 0.08
Multivariate analysis
Age 1.07 1.03, 1.11 0.001 1.05 1.02, 1.09 0.004 1.06 1.02, 1.09 0.003
Time to ROSC 1.07 1.03, 1.11 <0.001 1.11 1.06, 1.16 <0.001 1.11 1.07, 1.16 <0.001
Diabetes mellitus 2.87 1.19, 6.95 0.019 n.s. n.s.
PCI n.s. 0.09 0.01, 0.79 0.030 0.07 0.007, 0.61 0.017
OHCA, out-of-hospital cardiac arrest; VF, ventricular fibrillation; VT, ventricular tachycardia; CPR, cardiopulmonary resuscitation; hs-TnT, high-sensitivity troponin
T ROSC, return of spontaneous circulation; PCI, percutaneous coronary intervention; n.s., non-significant.
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The main finding of this study was that hs-TnT levels were
above the 99th percentile in all critically ill patients
successfully resuscitated from OHCA after VF or VT.
However, hs-TnT measurements on admission or later
during the ICU stay did not provide incremental
prognostic information about hospital mortality or 1-year
neurological outcome. hs-TnT dynamics during the ICU
stay also failed to provide prognostic information, and the
lack of prognostic information obtained from hs-TnT
measurement was evident for both hospital and 1-year
mortality.
Several factors may explain the limited prognostic
information by measuring hs-TnT levels in patients
with OHCA-VF/VT. First, myocardial cell necrosis is
not the main determinant of outcome after cardiac
arrest [4-6]. Hence, in patients with OHCA-VF/VT other
factors such as brain injury and the systemic ischemia/
reperfusion syndrome will be of greater importance
for short- and long-term outcome [7]. Deaths during
follow up may also relate to the initial brain injury, for
example, patients with poor cognitive function after
OHCA-VF/VT will be susceptible to dying from pneumoniaor other infections during follow up. Thus, unlike the
situation in chest-pain patients, pathology not reflected
by hs-TnT levels is likely to determine survival after
cardiac arrest.
Second, the influence of several factors besides acute
coronary artery occlusion to hs-TnT levels may attenuate
the prognostic value of hs-TnT in OHCA-VF/VT patients.
The duration of cardiopulmonary resuscitation and number
of defibrillation shocks have previously been reported to
increase troponin levels [25-27], and we also found the time
to ROSC to be closely associated with admission hs-TnT
levels. Impaired renal function was also associated with
increased hs-TnT levels in OHCA-VF/VT patients and this
association is well-known from previous studies [16-18,23].
In contrast, it is surprising that a previous diagnosis of
heart failure was associated with lower hs-TnT levels in our
study as patients with heart failure in general will have high
troponin levels [28]. A possible explanation for this result
could be less concomitant acute coronary artery occlusion
in heart failure patients with OHCA-VF/VT, thus,
heart failure patients with OHCA-VF/VT will have elevated
hs-TnT levels compared to the general population,
but still lower levels compared to other patients with
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in this study support this model. Previous studies using
older troponin assays have also found troponin levels to
exceed the upper reference limit in the majority of OHCA
patients [29-31].
We now support and extend these observations by
reporting hs-TnT levels above the 99th percentile of the
healthy population in all patients with OHCA-VF/VT.
The high troponin levels in OHCA-VF/VT patients are
likely a result of prolonged cardiopulmonary resuscitation,
multiple defibrillation shocks, and a proportion of the
patients having acute coronary artery occlusion as the
cause of OHCA-VF/VT. Of note, the results for hs-TnT
in OHCA-VF/VT are analogous to the situation for
hs-TnT measurements in other cohorts of critically ill
patients, including in severe sepsis where hs-TnT levels
are elevated in the majority of patients, but fail to improve
risk assessment beyond established risk indices [32].
Our study has several strengths. First, an obvious strength
is that the OHCA-VF/VT patients in this biomarker
substudy were comparable to the OHCA-VF/VT patients
in the large observational FINNRESUSCI study and should
therefore be representative of the general OHCA-VF/VT
cohort. In addition, a high proportion of patients (86%)
were treated with TH according to the current guidelines.
These two issues increase the external validity of our find-
ings. We also measured troponin T levels at several time
points by a high-sensitivity assay, which allowed us to assess
the relevance of troponin dynamics. However, any infer-
ences based on the findings of this study are subject to
some obvious limitations. First, we were not able to study
consecutive patients due to the requirement of written
informed consent for blood sampling. Second, the majority
of our patients were not examined by angiography,
although the proportion in our study were comparable to
the proportion examined by angiography in the main
FINNRESUSCI Study [20] and in other studies [29,31]. Our
study was not designed to assess the potential of hs-TnT to
diagnose acute coronary occlusion and hs-TnT levels
could still be of value for selecting patients who may
benefit from coronary revascularization in OHCA-VF/VT.
Furthermore, other cardiac biomarkers like the B-type
natriuretic peptides reflect additional pathophysiology
and may provide stronger prognostic information in
OHCA-VF/VT than hs-TnT levels. Finally, the study
patients were treated according to the current guidelines
proposing TH (33 to 34°C), and the results may be differ-
ent in future populations if milder hypothermia (36°C) will
be recommended [33].
Conclusion
We found hs-TnT levels to exceed the 99th percentile in
successfully resuscitated OHCA-VF/VT patients admitted
to the ICU. However, our data do not support the use ofhs-TnT measurements for risk stratification in critically ill
OHCA-VF/VT patients.
Key messages
 hs-TnT levels were elevated in all patients with
OHCA-VF/VT
 Admission hs-TnT levels were higher in 1-year
non-survivors and patients with an unfavorable
neurological outcome after 1 year
 hs-TnT measurements did not add to current risk
variables in OHCA-VF/VT.
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